ArticleMemorias do Instituto Oswaldo Cruz2025
Susceptibility of Aedes aegypti to spinosad larvicide and space spray adulticides in Brazil.
Article in Memorias do Instituto Oswaldo Cruz, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current Knowledge on Insecticide Resistance inInsects · 2026Review
- A Brief History of the Use of Insecticides in Brazil to Control Vector-Borne Diseases, and Implications for Insecticide Resistance.Tropical medicine and infectious disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsecticides play a critical role in controlling insect vectors, particularly during epidemics. Effective chemical control relies on the robust monitoring of insecticide resistance to guide evidence-based decision-making in vector control strategies.
objectivesThis study assessed the susceptibility of Aedes aegypti, the primary vector of dengue, Zika, and Chikungunya viruses, to various larvicides and adulticides deployed during Brazil's national campaigns from 2020 to 2023.
methodsMosquito collection was performed in 46 Brazilian municipalities using ovitraps. Eggs were transported to FIOCRUZ to establish the F1 and F2 generations. The Rockefeller strain was employed to determine the discriminating concentrations (DC) for the larvicide Natular™ 20EC (spinosad) and the adulticides Cielo™ (imidacloprid and prallethrin) and Fludora® Fusion (clothianidin and deltamethrin) using a modified World Health Organization (WHO) bottle bioassay. These DCs were then used to estimate the resistance status of Ae. aegypti populations in the tested formulations. Resistance intensity was assessed by exposing mosquitoes to five, 10, or 20 times the DC concentrations.
findingsAll Ae. aegypti populations were fully susceptible to larvicide spinosad. However, resistance to both adulticide formulations was detected based on WHO criteria (mortality rates < 90%). Intensity assays revealed high to very high resistance to combined adulticide products. MAIN
conclusionsOur findings indicate the full susceptibility of Ae. aegypti populations in Brazil to spinosad, but substantial resistance to adulticides used in space spraying and residual applications, likely due to pre-existing pyrethroid resistance. However, the specific contributions of each active ingredient remain unclear, owing to the evaluation of the combined formulations. The efficacy of both traditional and alternative vector control strategies must be continuously evaluated and closely monitored to ensure the real-time assessment of their performance. For chemical control, future studies should prioritise the assessment of combination products in field trials, refining laboratory assays, and sustaining insecticide resistance surveillance to optimise control efforts in Brazil.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.